Specific therapies include ERT [38], drug molecular chaperone therapy [39, 40], substrate reduction therapy, and gene therapy [41, 42], which can alleviate organ damage by increasing or restoring α-Gal A enzyme activity and reducing substrate GL-3 storage, bringing new hope to patients with Fabry disease. The gene discussed is ELF3; the disease is Fabry disease.